These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38561750)

  • 1. MicroRNA-21a-5p inhibition alleviates systemic sclerosis by targeting STAT3 signaling.
    Park JS; Kim C; Choi J; Jeong HY; Moon YM; Kang H; Lee EK; Cho ML; Park SH
    J Transl Med; 2024 Apr; 22(1):323. PubMed ID: 38561750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amelioration of tissue fibrosis by toll-like receptor 4 knockout in murine models of systemic sclerosis.
    Takahashi T; Asano Y; Ichimura Y; Toyama T; Taniguchi T; Noda S; Akamata K; Tada Y; Sugaya M; Kadono T; Sato S
    Arthritis Rheumatol; 2015 Jan; 67(1):254-65. PubMed ID: 25302613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Fibrosis and Immunological Features of Hypochlorous Acid Induced Mouse Model of Systemic Sclerosis.
    Meng M; Tan J; Chen W; Du Q; Xie B; Wang N; Zhu H; Wang K
    Front Immunol; 2019; 10():1861. PubMed ID: 31481954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid cell-specific deletion of Capns1 prevents macrophage polarization toward the M1 phenotype and reduces interstitial lung disease in the bleomycin model of systemic sclerosis.
    Zhang L; Zheng D; Yan Y; Yu Y; Chen R; Li Z; Greer PA; Peng T; Wang Q
    Arthritis Res Ther; 2022 Jun; 24(1):148. PubMed ID: 35729674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifibrotic effects and mechanisms of mesenchymal stem cell-derived exosomes in a systemic sclerosis mouse model: Possible contribution of miR-196b-5p.
    Baral H; Uchiyama A; Yokoyama Y; Sekiguchi A; Yamazaki S; Amalia SN; Inoue Y; Ogino S; Torii R; Hosoi M; Matsuzaki T; Motegi SI
    J Dermatol Sci; 2021 Oct; 104(1):39-47. PubMed ID: 34479773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Anti-S100A4 Monoclonal Antibody Treatment on Experimental Skin Fibrosis and Systemic Sclerosis-Specific Transcriptional Signatures in Human Skin.
    Trinh-Minh T; Györfi AH; Tomcik M; Tran-Manh C; Zhou X; Dickel N; Tümerdem BS; Kreuter A; Burmann SN; Borchert SV; Hussain RI; Hallén J; Klingelhöfer J; Kunz M; Distler JHW
    Arthritis Rheumatol; 2024 May; 76(5):783-795. PubMed ID: 38108109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of TLR7 and TLR9 in the Pathogenesis of Systemic Sclerosis.
    Wang C; Oishi K; Kobayashi T; Fujii K; Horii M; Fushida N; Kitano T; Maeda S; Ikawa Y; Komuro A; Hamaguchi Y; Matsushita T
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifibrotic effects of crocetin in scleroderma fibroblasts and in bleomycin-induced sclerotic mice.
    Song Y; Zhu L; Li M
    Clinics (Sao Paulo); 2013 Oct; 68(10):1350-7. PubMed ID: 24212843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The involvement of leucine-rich α-2 glycoprotein in the progression of skin and lung fibrosis in bleomycin-induced systemic sclerosis model.
    Nakajima H; Nakajima K; Serada S; Fujimoto M; Naka T; Sano S
    Mod Rheumatol; 2021 Nov; 31(6):1120-1128. PubMed ID: 33535851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A convenient method for producing the bleomycin-induced mouse model of scleroderma by weekly injections using a methylcellulose gel.
    Jun JB; Kim JK; Na YI; Jang SM; Paik SS; Kim YH
    Rheumatol Int; 2012 May; 32(5):1443-7. PubMed ID: 21448642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential roles of interleukin-17A in the development of skin fibrosis in mice.
    Okamoto Y; Hasegawa M; Matsushita T; Hamaguchi Y; Huu DL; Iwakura Y; Fujimoto M; Takehara K
    Arthritis Rheum; 2012 Nov; 64(11):3726-35. PubMed ID: 22833167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel bispecific antibody alleviates bleomycin-induced systemic sclerosis injury.
    Yin Q; Pi X; Ren G; Liu Z; Liu H; Wang M; Hu C; Zhao H; Li D; Yin J
    Int Immunopharmacol; 2020 Aug; 85():106644. PubMed ID: 32474387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new player in the game: treatment with antagomiR-21a-5p significantly attenuates histological and echocardiographic effects of experimental autoimmune myocarditis.
    Mirna M; Paar V; Topf A; Kraus T; Sotlar K; Aigner A; Ewe A; Watzinger S; Podesser BK; Hackl M; Pistulli R; Hoppe UC; Kiss A; Lichtenauer M
    Cardiovasc Res; 2022 Jan; 118(2):556-572. PubMed ID: 33483746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis.
    Lei L; Zhao C; Qin F; He ZY; Wang X; Zhong XN
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):14-22. PubMed ID: 26750756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of a humanized animal model of systemic sclerosis in which T helper-17 cells from patients with systemic sclerosis infiltrate and cause fibrosis in the lungs and skin.
    Park MJ; Park Y; Choi JW; Baek JA; Jeong HY; Na HS; Moon YM; Cho ML; Park SH
    Exp Mol Med; 2022 Sep; 54(9):1577-1585. PubMed ID: 36175484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A profibrotic role for thymic stromal lymphopoietin in systemic sclerosis.
    Usategui A; Criado G; Izquierdo E; Del Rey MJ; Carreira PE; Ortiz P; Leonard WJ; Pablos JL
    Ann Rheum Dis; 2013 Dec; 72(12):2018-23. PubMed ID: 23413283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis.
    Desallais L; Avouac J; Fréchet M; Elhai M; Ratsimandresy R; Montes M; Mouhsine H; Do H; Zagury JF; Allanore Y
    Arthritis Res Ther; 2014 Jul; 16(4):R157. PubMed ID: 25059342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice.
    Taniguchi T; Asano Y; Akamata K; Noda S; Takahashi T; Ichimura Y; Toyama T; Trojanowska M; Sato S
    Arthritis Rheumatol; 2015 Feb; 67(2):517-26. PubMed ID: 25385187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCL17-mediated downregulation of type I collagen via MMP1 and miR-29 in skin fibroblasts possibly contributes to the fibrosis in systemic sclerosis.
    Shimada S; Makino K; Jinnin M; Sawamura S; Kawano Y; Ide M; Kajihara I; Makino T; Fukushima S; Ihn H
    J Dermatol Sci; 2020 Dec; 100(3):183-191. PubMed ID: 33055012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum microRNA screening and functional studies reveal miR-483-5p as a potential driver of fibrosis in systemic sclerosis.
    Chouri E; Servaas NH; Bekker CPJ; Affandi AJ; Cossu M; Hillen MR; Angiolilli C; Mertens JS; van den Hoogen LL; Silva-Cardoso S; van der Kroef M; Vazirpanah N; Wichers CGK; Carvalheiro T; Blokland SLM; Giovannone B; Porretti L; Marut W; Vigone B; van Roon JAG; Beretta L; Rossato M; Radstake TRDJ
    J Autoimmun; 2018 May; 89():162-170. PubMed ID: 29371048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.